Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024

InvestorPlace05-17

These strong buy biotech stocks are worth considering. Verve Therapeutics (VERV): Developing gene-editing therapies to treat cardiovascular diseases with key pipeline advancements planned for 2024. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2436994770?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-17 18:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2436994770","market":"us","top_or_hot":-1,"title":"Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024","media":"InvestorPlace","content":"<div>\n<p>These strong buy biotech stocks are worth considering.\nVerve Therapeutics (VERV): Developing gene-editing therapies to treat cardiovascular diseases with key pipeline advancements planned for 2024.\n...</p>\n\n<a href=\"https://investorplace.com/2024/05/wall-street-favorites-3-cathie-wood-stocks-with-strong-buy-ratings-for-may-2024/\">Source Link</a>\n\n</div>\n","source":"investorplace_stock_picks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-17 18:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2024/05/wall-street-favorites-3-cathie-wood-stocks-with-strong-buy-ratings-for-may-2024/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These strong buy biotech stocks are worth considering.\nVerve Therapeutics (VERV): Developing gene-editing therapies to treat cardiovascular diseases with key pipeline advancements planned for 2024.\n...</p>\n\n<a href=\"https://investorplace.com/2024/05/wall-street-favorites-3-cathie-wood-stocks-with-strong-buy-ratings-for-may-2024/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FDN","symbol_name":"First Trust Dow Jones Internet I","start_time":0,"source_url":"https://investorplace.com/2024/05/wall-street-favorites-3-cathie-wood-stocks-with-strong-buy-ratings-for-may-2024/","article_id":"2436994770","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2436994770","pubTimestamp":1715941620,"sourceInfo":{"source_id":"investorplace_stock_picks","name":"InvestorPlace stock picks"},"weMediaInfo":null,"summary":"These strong buy biotech stocks are worth considering.Verve Therapeutics : Developing gene-editing therapies to treat cardiovascular diseases with key pipeline advancements planned for 2024.Prime Medicine : Engaged in developing advanced gene-editing technology called prime editing, with plans to initiate clinical trials and advance preclinical studies in 2024.Exact Sciences : Specializes in cancer diagnostics, leveraging AI for early detection, and preparing for FDA approval and commercialization of Cologuard Plus.The ARK Innovation ETF  has come under the spotlight recently, and there are three Cathie Wood stocks to buy with strong buy ratings for investors to consider in May this year.One of the key characteristics of the ARK Innovation ETF is its concentrated portfolio, typically holding between 35 to 55 stocks. This approach allows the fund to make significant investments in companies that ARK Invest believes have the potential to revolutionize their respective industries. However","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"FDN":"First Trust Dow Jones Internet I","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4548":"巴美列捷福持仓","EXAS":"精密科学","PRME":"Prime Medicine, Inc.","QID":"纳指两倍做空ETF","ARKK":"ARK Innovation ETF","BK4539":"次新股",".IXIC":"NASDAQ Composite","VERV":"Verve Therapeutics","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","TQQQ":"纳指三倍做多ETF","PSQ":"纳指反向ETF","BK4585":"ETF&股票定投概念","BK4139":"生物科技","QLD":"纳指两倍做多ETF","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","QQQ":"纳指100ETF","SQQQ":"纳指三倍做空ETF","BK4588":"碎股","BK4550":"红杉资本持仓","BK4544":"ARK ETF合集"},"translate_title":"华尔街最爱：2024年5月3只获得强烈买入评级的凯西伍德股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARKK":1,"VERV":1,"PRME":1,"EXAS":1,".IXIC":0.6,"TQQQ":0.6,"SQQQ":0.6,"QQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6,"FDN":0.6},"content_text":"These strong buy biotech stocks are worth considering.\nVerve Therapeutics (VERV): Developing gene-editing therapies to treat cardiovascular diseases with key pipeline advancements planned for 2024.\nPrime Medicine (PRME): Engaged in developing advanced gene-editing technology called prime editing, with plans to initiate clinical trials and advance preclinical studies in 2024.\nExact Sciences (EXAS): Specializes in cancer diagnostics, leveraging AI for early detection, and preparing for FDA approval and commercialization of Cologuard Plus.\n\n\n\n\n\n \n\nSource: shutterstock.com/viewimage\n\n\n\nThe ARK Innovation ETF (NYSEARCA:ARKK) has come under the spotlight recently, and there are three Cathie Wood stocks to buy with strong buy ratings for investors to consider in May this year.One of the key characteristics of the ARK Innovation ETF is its concentrated portfolio, typically holding between 35 to 55 stocks. This approach allows the fund to make significant investments in companies that ARK Invest believes have the potential to revolutionize their respective industries. However, this concentration also comes with a higher level of risk compared to more diversified funds.\nThe ETF has gained popularity among investors who believe in the long-term potential of disruptive technologies and are willing to accept the volatility that comes with investing in high-growth companies.\nSo with that being said, here are three Cathie Wood stocks that have strong buy ratings as of May this year.\nVerve Therapeutics (VERV)\nSource: Panuwach/ShutterstockVerve Therapeutics (NASDAQ:VERV) is focused on developing gene-editing therapies to treat cardiovascular diseases. The company is pioneering a new approach using base editing technology to transform the treatment of heart disease by addressing its underlying genetic causes.\nFor 2023, Verve reported a net loss of $200.1 million, reflecting a 27% increase from the previous year, driven by higher research and development expenses. Despite these losses, the company achieved significant revenue growth, reporting $11.8 million in 2023, up from $1.94 million in 2022.\nIn 2024, Verve plans to advance its pipeline with several key initiatives. The company aims to complete enrollment for the Heart-1 trial, which evaluates VERVE-101, by the end of the year and provide a data update in the second half of 2024. \nAdditionally, Verve has initiated the Heart-2 Phase 1b clinical trial of VERVE-102 and expects to start a Phase 1b trial for VERVE-201 in the second half of 2024.\nVERV has a consensus Strong Buy rating from seven analysts and a predicted upside of 420.55% over the next twelve months.\nPrime Medicine (PRME)\nSource: vxhal/ShutterStock.comPrime Medicine (NASDAQ:PRME) is engaged in the development of a more advanced gene-editing technology called prime editing. This method aims to precisely edit DNA without cutting it, offering potential treatments for a range of genetic disorders.\nARKK holds 2,591,955 shares of PRME, which accounts for 0.25% of its total weighting. \nIn 2024, the company plans to initiate an IND application for PM359, targeting Chronic Granulomatous Disease (CGD), with clinical trials expected to start later in the year. Additionally, Prime Medicine is advancing its Shielded Hematopoietic Stem Cell (HSC) and Immunotherapy Pairs (SCIP) technology, and plans to establish proof-of-concept for these approaches within the year.\nThe company also aims to continue preclinical studies for its liver programs and initiate IND-enabling activities for at least one liver program in 2024, targeting an IND or clinical trial application by 2025.\nThe ratings of nine analysts have contributed to PRME’s strong buy rating and it has an implied upside of 141.57%.\nExact Sciences (EXAS)\nSource: ShutterstockExact Sciences (NASDAQ:EXAS) specializes in cancer diagnostics and has leveraged AI to enhance its early detection capabilities. The company’s flagship product, Cologuard, is a non-invasive test for colorectal cancer screening.\nIn the first quarter of 2024, Exact Sciences reported revenue of $637.5 million, a 5.8% increase from the same period in 2023. However, the company faced a net loss of $110 million, or $0.60 per share, which was deeper than the previous year’s loss.\nThe company is also preparing for the FDA approval and commercialization of Cologuard Plus, which incorporates novel biomarkers and improved laboratory processes. Additionally, Exact Sciences is advancing its Precision Oncology portfolio, including the Oncotype DX Breast Recurrence Score.\nEXAS has a strong buy rating, which is a consensus from twelve analysts. It also has a consensus upside of 69.52% at the time of writing.\nIn conclusion, if one wants to choose one of those Cathie Wood stocks to buy in the biotech sector, then VERV, PRME, or EXAS could be the winning ticket.\nOn the date of publication, Matthew Farley did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.\nMatthew started writing coverage of the financial markets during the crypto boom of 2017 and was also a team member of several fintech startups. He then started writing about Australian and U.S. equities for various publications. His work has appeared in MarketBeat, FXStreet, Cryptoslate, Seeking Alpha, and the New Scientist magazine, among others.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/2024/05/wall-street-favorites-3-cathie-wood-stocks-with-strong-buy-ratings-for-may-2024/.\n©2024 InvestorPlace Media, LLC","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2436994770"}